{
    "data": [
        {
            "id": "4212056",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-17T02:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Wedgewood Partners Q3 2018 Client Letter: Anatomy Of A Bull Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103612",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "576527",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4212056-wedgewood-partners-q3-2018-client-letter-anatomy-of-bull-market"
            }
        },
        {
            "id": "4200106",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-17T13:01:33-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Good For The Heart And Your Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24992",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "18697",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4200106-edwards-lifesciences-good-for-heart-and-your-portfolio"
            }
        },
        {
            "id": "4173178",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-12T02:32:25-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Treating The #1 Killer In America",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103145",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "15103",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4173178-edwards-lifesciences-treating-1-killer-in-america"
            }
        },
        {
            "id": "4163407",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-17T05:22:26-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Wedgewood Partners Q1 2018 Client Letter - Hello Volatility, My Old Friend, I've Come To Talk With You Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103612",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "576527",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4163407-wedgewood-partners-q1-2018-client-letter-hello-volatility-old-friend-come-to-talk-you-again"
            }
        },
        {
            "id": "4160615",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-02T16:19:42-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Decelerating Fundamental Growth, Skyrocketing Stock Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104372",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "13765",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4160615-edwards-lifesciences-decelerating-fundamental-growth-skyrocketing-stock-price"
            }
        }
    ]
}